论文部分内容阅读
急性心肌梗死是临床常见病、多发病，病死率高，并有年轻化趋势，经皮冠状动脉介入治疗为临床有效治疗方法，但其可增加血栓形成，因此急性心肌梗死的抗栓治疗非常重要。替罗非班为血小板膜糖蛋白Ⅱb／Ⅲa受体拮抗剂，可有效抑制血栓形成，在急性心肌梗死经皮冠状动脉介入治疗患者中应用，可明显降低患者主要不良心血管事件发生率及病死率，有广阔的临床应用前景。“,”Acute myocardial infarction is a clinical common disease,frequently-occurring disease,with high case fatality and an earlier onset trend,and percutaneous coronary intervention is one of the effective meth-ods for the clinical treatment,but it may increase the risk of thrombosis,therefore,antithrombotic therapy is very important.Tirofiban is a receptor antagonist of platelet membrane glycoprotein Ⅱb/Ⅲa, which can inhibit thrombosis effectively.Tirofiban is applied in patients with acute myocardial infarction undergoing per-cutaneous coronary interventional therapy,which can obviously reduce the incidence of major adverse cardiac events and fatality,thus has a wide prospect of clinical application.